- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06382142
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
May 11, 2024 updated by: Sichuan Baili Pharmaceutical Co., Ltd.
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
436
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sa Xiao, PHD
- Phone Number: +8615013238943
- Email: xiaosa@baili-pharm.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Fudan University Shanghai Cancer Center
-
Contact:
- Jiong Wu
-
Principal Investigator:
- Jian Zhang
-
Principal Investigator:
- Jiong Wu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily sign the informed consent and follow the requirements of the protocol;
- No gender limit;
- Age ≥18 years old and ≤75 years old;
- Expected survival time ≥3 months;
- Patients with unresectable, locally advanced or metastatic triple-negative breast cancer;
- Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;
- The subjects had received 1-2 lines of chemotherapy regimens in the locally advanced or metastatic stage, and had been treated with taxanes previously;
- Acceptability of chemotherapy with eribulin, capecitabine, gemcitabine, or vinorelbine, as assessed by the investigator;
- Patients with baseline brain metastases should have received treatment for all brain metastases and be stable;
- Must have at least one measurable lesion that meets the RECIST v1.1 definition;
- ECOG score 0 or 1;
- Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the organ function level must meet the requirements;
- Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5×ULN;
- Urine protein ≤2+ or < 1000mg/24h;
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Prior receipt of an ADC with a TOPI inhibitor as a toxin;
- Prior receipt of an ADC or antibody drug targeting EGFR and/or HER3;
- Chemotherapy, biological therapy, immunotherapy, etc. within 4 weeks or 5 half-lives before the first dose, small molecule targeted therapy within 5 days, palliative radiotherapy and anti-tumor therapy within 2 weeks;
- Anthracycline equivalent cumulative dose of adriamycin > 360 mg/m2;
- History of severe cardiovascular or cerebrovascular disease;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Active malignancy diagnosed within 5 years before randomization;
- Hypertension poorly controlled by two antihypertensive drugs;
- Patients with poor blood glucose control before the first dose;
- A history of interstitial lung disease requiring steroid therapy, or current radiation pneumonitis, or a suspicion of such disease;
- Complicated with pulmonary diseases leading to clinically severe respiratory impairment;
- Patients with carcinomatous meningitis (meningeal metastasis) or brain stem metastasis or spinal cord compression;
- Have a history of allergy to recombinant humanized antibodies or any of the ingredients of BL-B01D1;
- A history of autologous or allogeneic stem cell transplantation;
- Human immunodeficiency virus antibody positive, active hepatitis B virus infection, or hepatitis C virus infection;
- Severe infection within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;
- Patients with massive or symptomatic effusions or poorly controlled effusions;
- Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
- Were receiving long-term systemic corticosteroids or equivalent active anti-inflammatory drugs or any form of immunosuppressive therapy before randomization;
- Received other unmarketed investigational drug or treatment within 4 weeks before the first dose;
- Patients with superior vena cava syndrome should not be rehydrated;
- A history of severe neurological or mental illness;
- Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea;
- Patients scheduled for vaccination or receiving live vaccine within 28 days before the first dose;
- Other circumstances that were assessed by the investigator as inappropriate for participation in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BL-B01D1
Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous infusion for a cycle of 3 weeks.
|
Experimental: Eribulin or Vinorelbine or Gemcitabine or Capecitabine
Participants receive Eribulin or Vinorelbine or Gemcitabine or Capecitabine in the first cycle (3 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous bolus for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 3 weeks.
Oral administration for a cycle of 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Up to approximately 24 months
|
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
|
Up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to approximately 24 months
|
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.
|
Up to approximately 24 months
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).
|
Up to approximately 24 months
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 24 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.
|
Up to approximately 24 months
|
Duration of Response (DOR)
Time Frame: Up to approximately 24 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.
|
Up to approximately 24 months
|
Treatment Emergent Adverse Event (TEAE)
Time Frame: Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1.
The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.
|
Up to approximately 24 months
|
Anti-drug antibody (ADA)
Time Frame: Up to approximately 24 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated.
|
Up to approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jian Zhang, Fudan University
- Principal Investigator: Jiong Wu, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
May 1, 2026
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
April 19, 2024
First Submitted That Met QC Criteria
April 19, 2024
First Posted (Actual)
April 24, 2024
Study Record Updates
Last Update Posted (Actual)
May 14, 2024
Last Update Submitted That Met QC Criteria
May 11, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Capecitabine
- Vinorelbine
- Gemcitabine
Other Study ID Numbers
- BL-B01D1-307
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple-Negative Breast Cancer
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on BL-B01D1
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingSolid Tumor | Gynecological Malignant TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingGastrointestinal TumorChina
-
SystImmune Inc.RecruitingBreast Cancer | Small Cell Lung Cancer | Nasopharyngeal Cancer | Esophageal Cancer | NSCLC | Lung Cancer | Non Small Cell Lung Cancer | SCLC | NPCUnited States
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingSolid Tumor | Urinary System TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.RecruitingLocally Advanced or Metastatic Solid TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.Recruiting
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingNasopharyngeal Carcinoma | Non-small Cell Lung CancerChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingBreast Cancer | Solid TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic Urinary Tumors | Other Solid TumorsChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingSolid Tumor | Urothelial CarcinomaChina